Interventions to inhibit oxidative stress and apoptosis, important pathogenic contributors toward the progression of chronic kidney disease (CKD), are not well established. Here, we investigated the role of a transforming growth factor beta (TGFβ) superfamily neutralizing protein, follistatin (FST), in the regulation of apoptosis and oxidative stress in glomerular mesangial cells (MCs) and in the progression of CKD.
Results:
The endoplasmic reticulum (ER) stress inducer thapsigargin (Tg), known to cause MC apoptosis, led to a post-translational increase in the expression of FST. Recombinant FST protected, whereas FST downregulation augmented, Tg-induced apoptosis without affecting Ca2+ release or ER stress induction. Although activins are the primary ligands neutralized by FST, their inhibition with neutralizing antibodies did not affect Tg-induced apoptosis. Instead, FST protected against Tg-induced apoptosis through neutralization of reactive oxygen species (ROS) independently of its ability to neutralize activins. Importantly, administration of FST to mice with CKD protected against renal cell apoptosis and oxidative stress. This was associated with improved kidney function, reduced albuminuria, and attenuation of fibrosis.
Innovation and Conclusion:
Independent of its activin neutralizing ability, FST protected against Tg-induced apoptosis through neutralization of ROS and consequent suppression of oxidative stress, seen both in vitro and in vivo. Importantly, FST also ameliorated fibrosis and improved kidney function in CKD. FST is, thus, a novel potential therapeutic agent for delaying the progression of CKD. Antioxid. Redox Signal. 31, 551–571.
Get full access to this article
View all access options for this article.
References
1.
AgapovaOA, FangY, SugataniT, SeifertME, and HruskaKA. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int, 89: 1231–1243, 2016.
2.
AllenL, DockrellDH, PatteryT, LeeDG, CornelisP, HellewellPG, and WhyteMKB. Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J Immunol, 174: 3643–3649, 2005.
3.
AokiF, KurabayashiM, HasegawaY, and KojimaI. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med, 172: 713–720, 2005.
4.
BaiX, LiX, TianJ, XuL, WanJ, and LiuY. A new model of diabetic nephropathy in C57BL/6 mice challenged with advanced oxidation protein products. Free Radic Biol Med, 118: 71–84, 2018.
5.
BondiCD, ManickamN, LeeDY, BlockK, GorinY, AbboudHE, and BarnesJL. NAD(P)H oxidase mediates TGF-beta 1-induced activation of kidney myofibroblasts. J Am Soc Nephrol, 21: 93–102, 2010.
6.
BurlakaI, NilssonLM, ScottL, HoltbäckU, EklöfAC, FogoAB, BrismarH, and AperiaA. Prevention of apoptosis averts glomerular tubular disconnection and podocyte loss in proteinuric kidney disease. Kidney Int, 90: 135–148, 2016.
7.
ChenW, WoodruffTK, and MayoKE. Activin A-induced HepG2 liver cell apoptosis: Involvement of activin receptors and Smad proteins. Endocrinology, 141: 1263–1272, 2000.
8.
ChongZ, DongP, RiazH, ShiL, YuX, ChengY, and YangL. Disruption of follistatin by RNAi increases apoptosis, arrests S-phase of cell cycle and decreases estradiol production in bovine granulosa cells. Anim Reprod Sci, 155: 80–88, 2015.
9.
CoutinhoLM, VieiraEL, Dela CruzC, CasalechiM, TeixeiraAL, Del PuertoHL, and ReisFM. Apoptosis modulation by activin A and follistatin in human endometrial stromal cells. Gynecol Endocrinol, 32: 161–165, 2016.
10.
DickhoutJG and KrepinskyJC. Endoplasmic reticulum stress and renal disease. Antioxid Redox Signal, 11: 2341–2352, 2009.
11.
DrögeW. Free radicals in the physiological control of cell function. Physiol Rev, 82: 47–95, 2002.
12.
GaoX, DongH, LinC, ShengJ, ZhangF, SuJ, and XuZ. Reduction of AUF1-mediated follistatin mRNA decay during glucose starvation protects cells from apoptosis. Nucleic Acids Res, 42: 10720–10730, 2014.
13.
GaoX, WeiS, LaiK, ShengJ, SuJ, ZhuJ, DongH, HuH, and XuZ. Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis. J Biol Chem, 285: 36857–36864, 2010.
14.
GavaAL, FreitasFP, BalariniCM, VasquezEC, and MeyrellesSS. Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int J Physiol Pathophysiol Pharmacol, 4: 167–173, 2012.
15.
GorinY, BlockK, HernandezJ, BhandariB, WagnerB, BarnesJL, and AbboudHE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem, 280: 39616–39626, 2005.
16.
HakamiNY, WongH, ShahMH, DustingGJ, JiangF, and PeshavariyaHM. Smad-independent pathway involved in transforming growth factor β1-induced Nox4 expression and proliferation of endothelial cells. Naunyn Schmiedebergs Arch Pharmacol, 388: 319–326, 2015.
17.
HaridossS, YovchevMI, SchweizerH, MegherhiS, BeecherM, LockerJ, and OertelM. Activin A is a prominent autocrine regulator of hepatocyte growth arrest. Hepatol Commun, 1: 852–870, 2017.
18.
HashimotoO, NakamuraT, ShojiH, ShimasakiS, HayashiY, and SuginoH. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells: Endocytotic degradation of activin and its acceleration by Follistatin associated with cell-surface heparan sulfate. J Biol Chem, 272: 13835–13842, 1997.
19.
HedgerMP and De KretserDM. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev, 24: 285–295, 2013.
20.
HullyJR, ChangL, SchwallRH, WidmerHR, TerrellTG, and GillettNA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology, 20: 854–862, 1994.
21.
Iglesias-de la CruzMC, Ruiz-TorresP, AlcamíJ, Díez-MarquésL, Ortega-VelázquezR, ChenS, Rodríguez-PuyolM, ZiyadehFN, and Rodríguez-PuyolD. Hydrogen peroxide increases extracellular matrix mRNA through TGF-β in human mesangial cells. Kidney Int, 59: 87–95, 2001.
JhaJC, BanalC, ChowBSM, CooperME, and Jandeleit-DahmK. Diabetes and kidney disease: Role of oxidative stress. Antioxid Redox Signal, 25: 657–684, 2016.
24.
JhaV, Garcia-GarciaG, IsekiK, LiZ, NaickerS, PlattnerB, SaranR, WangAY-M, and YangC-W. Chronic kidney disease: Global dimension and perspectives. Lancet, 382: 260–272, 2013.
KangBPS, FrencherS, ReddyV, KesslerA, MalhotraA, and MeggsLG. High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. Am J Physiol Renal Physiol, 284: F455–F466, 2003.
27.
de KretserDM, O'HehirRE, HardyCL, and HedgerMP. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol, 359: 101–106, 2012.
28.
KurodaJ, AgoT, NishimuraA, NakamuraK, MatsuoR, WakisakaY, KamouchiM, and KitazonoT. Nox4 Is a major source of superoxide production in human brain pericytes. J Vasc Res, 8582: 429–438, 2015.
29.
LeelahavanichkulA, YanQ, HuX, EisnerC, HuangY, ChenR, MizelD, ZhouH, WrightEC, KoppJB, SchnermannJ, YuenPST, and StarRA. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int, 78: 1136–1153, 2010.
30.
LevineRL, MosoniL, BerlettBS, and StadtmanER. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci U S A, 93: 15036–15040, 1996.
31.
LiL and HuG. Pink1 protects cortical neurons from thapsigargin-induced oxidative stress and neuronal apoptosis. Biosci Rep, 35: 1–8, 2015.
32.
LiZL, ShiY, LeG, DingY, and ZhaoQ. 24-Week exposure to oxidized tyrosine induces hepatic fibrosis involving activation of the MAPK/TGF-β 1 signaling pathway in Sprague-Dawley rats model. Oxid Med Cell Longev, 2016: 1–12, 2016.
33.
LimR, AcharyaR, DelpachitraP, HobsonS, SobeyCG, DrummondGR, and WallaceEM. Activin and NADPH-oxidase in preeclampsia: Insights from in vitro and murine studies. Am J Obstet Gynecol, 212: 86.e1.e12–e86.e12, 2015.
34.
LinC, ZhaoX, SunD, ZhangL, FangW, ZhuT, WangQ, LiuB, WeiS, ChenG, XuZ, and GaoX. Transcriptional activation of follistatin by Nrf2 protects pulmonary epithelial cells against silica nanoparticle-induced oxidative stress. Sci Rep, 6: 21133, 2016.
35.
LiuM, MaoC, LiJ, HanF, and YangP. Effects of the activin A–follistatin system on myocardial cell apoptosis through the endoplasmic reticulum stress pathway in heart failure. Int J Mol Sci, 18: 374, 2017.
36.
LiuY, WangY, DingW, and WangY. Mito-TEMPO alleviates renal fibrosis by reducing inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress. Oxid Med Cell Longev, 2018: Article ID: 1–13, 2018.
37.
LuoS and LevineRL. Methionine in proteins defends against oxidative stress. FASEB J, 23: 464–472, 2009.
38.
LvW, BoozGW, FanF, WangY, and RomanRJ. Oxidative stress and renal fibrosis: Recent insights for the development of novel therapeutic strategies. Front Physiol, 9: 1–11, 2018.
39.
LyttonsgJ, WestlinsM, and HanleyllMR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem, 266: 17067–17071, 1991.
40.
MaZ, FanC, YangY, DiS, HuW, LiT, ZhuY, HanJ, XinZ, WuG, ZhaoJ, LiX, and YanX. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation. Sci Rep, 6: 35196, 2016.
41.
MaeshimaA, MishimaK, YamashitaS, NakasatomiM, MiyaM, SakuraiN, SakairiT, IkeuchiH, HiromuraK, HasegawaY, KojimaI, and NojimaY. Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction. Biomed Res Int, 2014: 376191, 2014.
42.
MakinoH, SugiyamaH, and KashiharaN. Apoptosis and extracellular matrix–cell interactions in kidney disease. Kidney Int, 58: S67–S75, 2000.
43.
ManaloRVM and MedinaPMB. The endoplasmic reticulum stress response in disease pathogenesis and pathophysiology. Egypt J Med Hum Genet, 19: 77–81, 2018.
44.
Mohammed-AliZ, LuC, MarwayMK, CarlisleRE, AskK, LukicD, KrepinskyJC, and DickhoutJG. Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria. Sci Rep, 7: 1–14, 2017.
45.
NasriH. Antioxidant therapy to ameliorate chronic kidney disease induced by oxidative stress; an updated mini-review. J Prev Epidemiol, 2: 22–25, 2017.
46.
NishiharaT, OkahashiN, and UedaN. Activin A induces apoptotic cell death. Biochem Biophys Res Commun, 197: 985–991, 1993.
47.
OslowskiCM and UranoF. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol, 490: 71–92, 2013.
48.
PatellaS, PhillipsDJ, TchongueJ, de KretserDM, and SievertW. Follistatin attenuates early liver fibrosis: Effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol, 290: G137–G144, 2006.
49.
QiY, GeJ, MaC, WuN, CuiX, and LiuZ. Activin A regulates activation of mouse neutrophils by Smad3 signalling. Open Biol, 7: 160342, 2017.
50.
RichterK and KietzmannT. Reactive oxygen species and fibrosis: Further evidence of a significant liaison. Cell Tissue Res, 365: 591–605, 2016.
51.
RocheM, RondeauP, SinghNR, TarnusE, and BourdonE. The antioxidant properties of serum albumin. FEBS Lett, 582: 1783–1787, 2008.
52.
RuizS, PergolaPE, ZagerRA, and VaziriND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int, 83: 1029–1041, 2013.
53.
SahniN and GuptaKL. Dietary antioxidents and oxidative stress in predialysis chronic kidney disease patients. J Nephropathol, 1: 134–142, 2012.
54.
SalahudeenAK, ClarkEC, and NathKA. Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J Clin Invest, 88: 1886–1893, 1991.
55.
SalehH, SchlatterE, LangD, PauelsHG, and HeidenreichS. Regulation of mesangial cell apoptosis and proliferation by intracellular Ca(2+) signals. Kidney Int, 58: 1876–1884, 2000.
56.
SanzAB, SantamariaB, Ruiz-OrtegaM, EgidoJ, and OrtizA. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol, 19: 1634–1642, 2008.
57.
SchlöndorffD and BanasB. The mesangial cell revisited: No cell is an island. J Am Soc Nephrol, 20: 1179–1187, 2009.
58.
SchwallRH, RobbinsK, JardieuP, ChangL, LaiC, and TerrellTG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology, 18: 347–356, 1993.
59.
SidisY, SchneyerAL, SlussPM, JohnsonLN, and KeutmannHT. Follistatin: Essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem, 276: 17718–17726, 2001.
60.
SiesH. Oxidative stress: From basic research to clinical application. Am J Med, 91: S31–S38, 1991.
61.
SimonHU, Haj-YehiaA, and Levi-SchafferF. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis, 5: 415–418, 2000.
62.
SriramS, SubramanianS, SathiakumarD, VenkateshR, SalernoMS, McfarlaneCD, KambadurR, and SharmaM. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB. Aging Cell, 10: 931–948, 2011.
63.
SugiyamaH, KashiharaN, MakinoH, YamasakiY, and OtaZ. Reactive oxygen species induce apoptosis in cultures human mesangial cells. J Am Soc Nephrol, 7: 2357–2363, 1997.
64.
SundaramMS, NagarajanS, JagdeeshwaranA, and DeviMA. Chronic kidney disease—Effect of oxidative stress. Chinese J Biol, 2014: 1–6, 2014.
65.
TanRJ, ZhouD, XiaoL, ZhouL, LiY, BastackySI, OuryTD, and LiuY. Extracellular superoxide dismutase protects against proteinuric kidney disease. J Am Soc Nephrol, 26: 2447–2459, 2015.
66.
ThannickalVJ and FanburgBL. Reactive oxygen species in cell signaling. Am J Physiol Cell Mol Physiol, 279: L1005–L1028, 2000.
67.
Valderrama-CarvajalH, CocolakisE, LacerteA, LeeEH, KrystalG, AliS, and LebrunJJ. Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol, 4: 963–969, 2002.
68.
WangC, LiT, TangS, ZhaoD, ZhangC, ZhangS, DengS, ZhouY, and XiaoX. Thapsigargin induces apoptosis when autophagy is inhibited in HepG2 cells and both processes are regulated by ROS-dependent pathway. Environ Toxicol Pharmacol, 41: 167–179, 2016.
69.
WangQ, KeutmannHT, SchneyerAL, and SlussPM. Analysis of human follistatin structure: Identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology, 141: 3183–3193, 2000.
70.
WangY, BranickyR, NoëA, and HekimiS. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol, 217: 1915–1928, 2018.
71.
YangQ, WuF, WangJ, GaoL, JiangL, LiH-D, MaQ, LiuX, WeiB, ZhouL, LiJ, and MengX. Nox4 in renal diseases: An update. Free Radic Biol Med, 124: 466–472, 2018.
72.
YumV, CarlisleRE, LuC, BrimbleE, ChahalJ, UpaguptaC, AskK, and DickhoutJG. Endoplasmic reticulum stress inhibition limits the progression of chronic kidney disease in the Dahl salt-sensitive rat. Am J Physiol Renal Physiol, 312: F230–F244, 2017.
73.
ZhangL, LiuK, HanB, XuZ, and GaoX. The emerging role of follistatin under stresses and its implications in diseases. Gene, 639: 111–116, 2018.
74.
ZhangY, LiuJ, TianXY, WongWT, ChenY, WangL, LuoJ, CheangWS, LauCW, KwanKM, WangN, YaoX, and HuangY. Inhibition of bone morphogenic protein 4 restores endothelial function in db/db diabetic mice. Arterioscler Thromb Vasc Biol, 34: 152–159, 2014.
75.
ZhangY, QiY, ZhaoY, SunH, GeJ, and LiuZ. Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway. Oncol Lett, 15: 2590–2594, 2017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
